Bioprinting has advanced rapidly through engineering step changes in the use of three-dimensional (3D) printing. With these developments, living cells can be positioned layer by layer to produce functional tissue structures. Key attributes of this emerging technology are its high scalability and modularity, which enable automated and repeatable manufacture of a wide variety of tissues. These high-throughput biofabrication capabilities equip companies with tools to develop 3D-printed tissues for broad applications, from in vitro drug testing models to therapeutic tissue implants, to whole organ transplants. In this article, the authors outline some of the major developments in the space, along with regulatory responses and potential hurdles going forward.
The science of credibility: Communicating complex science to diverse stakeholders
Effective delivery depends on whether the audience perceives both the message and its source as credible. CRA recently hosted a forum to discuss the importance...